Results 111 to 120 of about 22,537 (257)

Dual mTORC1/mTORC2 blocker as a possible therapy for tauopathy in cellular model

open access: yes, 2017
Tauopathy comprises a group of disorders caused by abnormal aggregates of tau protein. In these disorders phosphorylated tau protein tends to accumulate inside neuronal cells (soma) instead of the normal axonal distribution of tau.
Magdy, Alshimaa   +13 more
core   +1 more source

Lipid Dynamics in the Amyloid Cascade Hypothesis: Evaluating the Biological Relevance of In Vitro Models

open access: yesChemBioChem, Volume 27, Issue 11, 15 June 2026.
This review reconsiders the amyloid cascade by placing lipid dynamics at its core. It shows that free lipids, governed by critical micellar concentration, act as pathological chaperones that redirect amyloid aggregation toward membrane‐damaging species.
Sofia Serravalle   +6 more
wiley   +1 more source

Discovery and characterization of stereodefined PMO-gapmers targeting tau

open access: yesMolecular Therapy: Nucleic Acids
Antisense oligonucleotides (ASOs) are an important class of therapeutics to treat genetic diseases, and expansion of this modality to neurodegenerative disorders has been an active area of research.
Kunihiko Kanatsu   +25 more
doaj   +1 more source

Modulation of neuroinflammation and tauopathy by RNA-binding protein TIA1 in the P301S mouse model of tauopathy [PDF]

open access: yes, 2020
Tauopathies are a class of neurodegenerative diseases characterized by aggregation of hyperphosphorylated microtubule associated protein tau (phospho-tau), resulting in neuroinflammation and neurodegeneration. Neuroinflammatory processes play an integral
LeBlang, Chelsey Jenna
core  

A Systematic Comparison of Alpha‐Synuclein Seed Amplification Assays for Increasing Reproducibility

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1088-1105, June 2026.
ABSTRACT Seed amplification assays (SAAs) enable ultrasensitive detection of misfolded α‐synuclein across biofluids and tissues. Yet, heterogeneity in protocols limits cross‐study comparability and clinical translation. Here, we review α‐synuclein SAA methods and their performance across various biological matrices.
Manuela Amaral‐do‐Nascimento   +3 more
wiley   +1 more source

Tauopathy in the young autistic brain: novel biomarker and therapeutic target

open access: yes, 2020
: Given our recent discovery of somatic mutations in autism spectrum disorder (ASD)/intellectual disability (ID) genes in postmortem aged Alzheimer's disease brains correlating with increasing tauopathy, it is important to decipher if tauopathy is ...
Marusic, Zlatko   +12 more
core  

Autophagy gridlock in tauopathy

open access: yes, 2016
Tauopathies are a group of neurodegenerative diseases characterized by the presence of intracellular aggregates containing the microtubule associated protein tau. Bulk degradation of aggregation-prone proteins can occur via autophagy.
Bakhoum, Mathieu 1985-
core  

Visible Tongue Fasciculations With Electromyographic Denervation in Autopsy‐Proven Progressive Supranuclear Palsy Mimicking Amyotrophic Lateral Sclerosis

open access: yes
Muscle &Nerve, EarlyView.
Hiroyasu Inoue   +7 more
wiley   +1 more source

Sex differences in brain glucose metabolism and Alzheimer's disease risk and progression

open access: yesAlzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract Sex differences are increasingly recognized as central to the biology of Alzheimer's disease (AD), yet the mechanisms through which they shape brain metabolism and disease vulnerability remain incompletely understood. Brain glucose hypometabolism is a core hallmark of AD and emerges decades before clinical decline, but accumulating evidence ...
Marjan Ramezan   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy